• Species Reactivity

  Human

• Specificity

  Detects human IL-19 in direct ELISAs.

• Source

  Monoclonal Mouse IgG    _2B Clone # 152112

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  E. coli-derived recombinant human IL-19    
  Leu25-Ala177    
  Accession # AAN40906

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.10 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• CyTOF-ready

  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

• 
  

• Intracellular Staining by Flow Cytometry

  2.5 µg/10    ⁶ cells

  Human LPS-treated peripheral blood mononuclear cells fixed with paraformaldehyde and permeabilized with saponin

• 
  

• Neutralization

  Measured by its ability to neutralize IL‑19-induced proliferation in the BaF3 mouse pro‑B cell line co-transfected with human IL‑20 R alpha and IL‑20 R beta. The Neutralization Dose (ND    ₅₀) is typically 0.2-0.5 µg/mL in the presence of 3 ng/mL Recombinant Human IL‑19.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-19

Human Interleukin 19 (IL-19) is a member of the IL-10 family of related cytokines. Its gene contains two alternate translation initiation sites, generating precursors of 215 amino acids (aa) and 177 aa, respectively. Both isoforms are processed to 17 kDa, 153 aa mature molecules. IL-19 contains seven helices and is secreted as a 35 kDa monomer. There are two potential N-linked glycosylation sites, and it is likely that the molecule is glycosylated. Mature human IL-19 shares 69% aa sequence identity with the mature mouse homologue. Although mouse IL-19 is active on human cells, human IL-19 is not active on mouse cells. IL-19 expression is limited to activated keratinocytes and monocytes. IL-19 binds a receptor complex consisting of the IL-20 receptor alpha (IL-20 R alpha, also known as IL-20 R1) and the IL-20 receptor beta (IL-20 R beta or IL-20 R2). This receptor complex is also shared by IL-20 and IL-24. Functionally, IL-19 induces IL-6 and TNF-alpha production by monocytes, and drives T-helper cell differentiation towards a Th2 response (1‑5).

• References:

1. Gallagher, G. et al. (2000) Genes Immun. 1:442.

2. Gallagher, G. et al. (2004) Int. Immunopharmacol. 4:615.

3. Laio, Y-C. et al. (2002) J. Immunol. 169:4288.

4. Romer, J. et al. (2003) J. Invest. Dermatol. 121:1306.

5. Pestka, S. et al. (2004) Annu. Rev. Immunol. 22:929.

• Long Name:

  Interleukin 19

• Entrez Gene IDs:

  29949 (Human); 329244 (Mouse)

• Alternate Names:

  IL-10C; IL19; IL-19; interleukin 19; MDA1; melanoma differentiation associated protein-like protein; NG.1Melanoma differentiation-associated protein-like protein; ZMDA1interleukin-19